Isikdogan, A. Et Al. 2022. First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis. ANNALS OF ONCOLOGY , vol.33 .

Isikdogan, A., Turk, H., Bilir, C., Sendur, M., Karabulut, B., Artac, M., ... Cicin, I.(2022). First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis. ANNALS OF ONCOLOGY , vol.33.

Isikdogan, A. Et Al. "First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis," ANNALS OF ONCOLOGY , vol.33, 2022

Isikdogan, A. Et Al. "First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis." ANNALS OF ONCOLOGY , vol.33, 2022

Isikdogan, A. Et Al. (2022) . "First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis." ANNALS OF ONCOLOGY , vol.33.

@article{article, author={A. Isikdogan Et Al. }, title={First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis}, journal={ANNALS OF ONCOLOGY}, year=2022}